Activation‐induced cell death in T cells

Summary:  A properly functioning immune system is dependent on programmed cell death at virtually every stage of lymphocyte development and activity. This review addresses the phenomenon of activation‐induced cell death (AICD) in T lymphocytes, in which activation through the T‐cell receptor results in apoptosis. AICD can occur in a cell‐autonomous manner and is influenced by the nature of the initial T‐cell activation events. It plays essential roles in both central and peripheral deletion events involved in tolerance and homeostasis, although it is likely that different forms of AICD proceed via different mechanisms. For example, while AICD in peripheral T cells is often caused by the induction of expression of the death ligand, Fas ligand (CD95 ligand, FasL), it does not appear to be involved in AICD in thymocytes. This and other mechanisms of AICD are discussed. One emerging model that may complement other forms of AICD involves the inducible expression of FasL by nonlymphoid tissues in response to activated T lymphocytes. Induction of nonlymphoid FasL in this manner may serve as a sensing mechanism for immune cell infiltration, which contributes to peripheral deletion.

[1]  M. Seman,et al.  A delayed-type hypersensitivity reaction initiated by a single T lymphocyte , 1981, Agents and Actions.

[2]  Y. Wan,et al.  The survival of antigen-stimulated T cells requires NFkappaB-mediated inhibition of p73 expression. , 2003, Immunity.

[3]  D. Green.  The suicide in the thymus, a twisted trail , 2003, Nature Immunology.

[4]  YOUHAI H. Chen,et al.  Defective thymocyte apoptosis and accelerated autoimmune diseases in TRAIL−/− mice , 2003, Nature Immunology.

[5]  D. Green,et al.  Nonlymphoid Fas ligand in peptide-induced peripheral lymphocyte deletion , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[6]  Hae-Ock Lee,et al.  TRAIL: A Mechanism of Tumor Surveillance in an Immune Privileged Site1 , 2002, The Journal of Immunology.

[7]  A. Strasser,et al.  Peripheral Deletion of Autoreactive CD8 T Cells by Cross Presentation of Self-Antigen Occurs by a Bcl-2–inhibitable Pathway Mediated by Bim , 2002, The Journal of experimental medicine.

[8]  D. Green,et al.  Metalloproteinase Shedding of Fas Ligand Regulates β-Amyloid Neurotoxicity , 2002, Current Biology.

[9]  D. Green,et al.  Tumor necrosis factor alpha up-regulates non-lymphoid Fas-ligand following superantigen-induced peripheral lymphocyte activation. , 2002, The Journal of biological chemistry.

[10]  A. Strasser,et al.  Activated T cell death in vivo mediated by proapoptotic bcl-2 family member bim. , 2002, Immunity.

[11]  N. Mounier,et al.  CD95 engagement induces disseminated endothelial cell apoptosis in vivo: immunopathologic implications. , 2002, Blood.

[12]  M. Karin,et al.  Missing Pieces in the NF-κB Puzzle , 2002, Cell.

[13]  A. Strasser,et al.  BH3-only Bcl-2 family member Bim is required for apoptosis of autoreactive thymocytes , 2002, Nature.

[14]  L. Kirshenbaum,et al.  Suppression of Akt Signaling Induces Fas Ligand Expression: Involvement of Caspase and Jun Kinase Activation in Akt-Mediated Fas Ligand Regulation , 2002, Molecular and Cellular Biology.

[15]  D. Green,et al.  Metalloproteinase shedding of Fas ligand regulates beta-amyloid neurotoxicity. , 2002, Current biology : CB.

[16]  D. Green,et al.  The role of Fas ligand in immune privilege , 2001, Nature Reviews Molecular Cell Biology.

[17]  M. Greenberg,et al.  β-Amyloid Induces Neuronal Apoptosis Via a Mechanism that Involves the c-Jun N-Terminal Kinase Pathway and the Induction of Fas Ligand , 2001, The Journal of Neuroscience.

[18]  A. Khoruts,et al.  Visualizing the generation of memory CD4 T cells in the whole body , 2001, Nature.

[19]  M. Delgado,et al.  Vasoactive Intestinal Peptide and Pituitary Adenylate Cyclase-Activating Polypeptide Inhibit Expression of Fas Ligand in Activated T Lymphocytes by Regulating c-Myc, NF-κB, NF-AT, and Early Growth Factors 2/31 , 2001, The Journal of Immunology.

[20]  A. Khoruts,et al.  In vivo activation of antigen-specific CD4 T cells. , 2001, Annual review of immunology.

[21]  Ruggero De Maria,et al.  Control of target cell survival in thyroid autoimmunity by T helper cytokines via regulation of apoptotic proteins , 2000, Nature Immunology.

[22]  W. Kaelin,et al.  A common E2F-1 and p73 pathway mediates cell death induced by TCR activation , 2000, Nature.

[23]  D. Green,et al.  A ‘non-canonical’ DNA-binding element mediates the response of the Fas-ligand promoter to c-Myc , 2000, Current Biology.

[24]  A. Ma,et al.  Failure to regulate TNF-induced NF-kappaB and cell death responses in A20-deficient mice. , 2000, Science.

[25]  A. Rao,et al.  Gene expression elicited by NFAT in the presence or absence of cooperative recruitment of Fos and Jun , 2000, The EMBO journal.

[26]  B. Morgan,et al.  Role and regulation of pig CD59 and membrane cofactor protein/CD46 expressed on pig aortic endothelial cells. , 2000, Transplantation.

[27]  M. V. D. van den Brink,et al.  Fas ligand-deficient gld mice are more susceptible to graft-versus-host-disease. , 2000, Transplantation.

[28]  D. Green,et al.  Regulation of FasL by NF-κB and AP-1 in Fas-dependent Thymineless Death of Human Colon Carcinoma Cells* , 2000, The Journal of Biological Chemistry.

[29]  S. Moe,et al.  Opposing Effects of Transmembrane and Soluble FAS Ligand Expression on Inflammation and Tumor Cell Survival , 2000, The Journal of experimental medicine.

[30]  D. Metz,et al.  The liver as a site of T‐cell apoptosis: graveyard, or killing field? , 2000, Immunological reviews.

[31]  D. Green,et al.  Expression of Fas Ligand in Activated T Cells Is Regulated by c-Myc* , 2000, The Journal of Biological Chemistry.

[32]  D. Curiel,et al.  Antigen presenting cells expressing Fas ligand down-modulate chronic inflammatory disease in Fas ligand-deficient mice. , 2000, The Journal of clinical investigation.

[33]  L. Glimcher,et al.  Sequential involvement of NFAT and Egr transcription factors in FasL regulation. , 2000, Immunity.

[34]  M. Pinkoski,et al.  Fas ligand, death gene , 1999, Cell Death and Differentiation.

[35]  A. Strasser,et al.  Proapoptotic Bcl-2 relative Bim required for certain apoptotic responses, leukocyte homeostasis, and to preclude autoimmunity. , 1999, Science.

[36]  S. Ju,et al.  FasL promoter activation by IL‐2 through SP1 and NFAT but not Egr‐2 and Egr‐3 , 1999, European journal of immunology.

[37]  Marty W. Mayo,et al.  NF-κB Induces Expression of the Bcl-2 Homologue A1/Bfl-1 To Preferentially Suppress Chemotherapy-Induced Apoptosis , 1999, Molecular and Cellular Biology.

[38]  M. Kripke,et al.  Fas ligand: a sensor for DNA damage critical in skin cancer etiology. , 1999, Science.

[39]  A. Cross,et al.  Dual Role for Fas Ligand in the Initiation of and Recovery from Experimental Allergic Encephalomyelitis , 1999, The Journal of experimental medicine.

[40]  J. Baraban,et al.  The EGR family of transcription-regulatory factors: progress at the interface of molecular and systems neuroscience , 1999, Trends in Neurosciences.

[41]  C. Payá,et al.  Constitutive Fas Ligand Gene Transcription in Sertoli Cells Is Regulated By Sp1* , 1999, The Journal of Biological Chemistry.

[42]  M. Greenberg,et al.  Akt Promotes Cell Survival by Phosphorylating and Inhibiting a Forkhead Transcription Factor , 1999, Cell.

[43]  H. Kaplan,et al.  Fas ligand (CD95 ligand) controls angiogenesis beneath the retina , 1999, Nature Medicine.

[44]  J. Ashwell,et al.  Role of Egr-2 in Up-regulation of Fas Ligand in Normal T Cells and Aberrant Double-negative lpr and gld T Cells* , 1999, The Journal of Biological Chemistry.

[45]  D. Green,et al.  Transforming Growth Factor β1 Inhibits Fas Ligand Expression and Subsequent Activation-induced Cell Death in T Cells via Downregulation of c-Myc , 1999, The Journal of experimental medicine.

[46]  Ingo Schmitz,et al.  The Role of c-FLIP in Modulation of CD95-induced Apoptosis* , 1999, The Journal of Biological Chemistry.

[47]  D. Green,et al.  Regulation of Fas-Ligand Expression during Activation-induced Cell Death in T Lymphocytes via Nuclear Factor κB* , 1999, The Journal of Biological Chemistry.

[48]  D. Green,et al.  Withdrawal of Survival Factors Results in Activation of the JNK Pathway in Neuronal Cells Leading to Fas Ligand Induction and Cell Death , 1999, Molecular and Cellular Biology.

[49]  D. Longo,et al.  Bcl-2–mediated Drug Resistance: Inhibition of Apoptosis by Blocking Nuclear Factor of Activated T Lymphocytes (NFAT)-induced Fas Ligand Transcription , 1999 .

[50]  R. Siegel,et al.  Mature T lymphocyte apoptosis--immune regulation in a dynamic and unpredictable antigenic environment. , 1999, Annual review of immunology.

[51]  M. Todaro,et al.  Fas/Fas ligand-driven T cell apoptosis as a consequence of ineffective thyroid immunoprivilege in Hashimoto's thyroiditis. , 1999, Journal of immunology.

[52]  F. Shanahan,et al.  The Fas counterattack: cancer as a site of immune privilege. , 1999, Immunology today.

[53]  H. Nishimatsu,et al.  Accelerated rejection of Fas ligand-expressing heart grafts. , 1999, Journal of immunology.

[54]  D. Israeli,et al.  p53 Activates the CD95 (APO-1/Fas) Gene in Response to DNA Damage by Anticancer Drugs , 1998, The Journal of experimental medicine.

[55]  D. Green,et al.  Inducible nonlymphoid expression of Fas ligand is responsible for superantigen-induced peripheral deletion of T cells. , 1998, Immunity.

[56]  L. Glimcher,et al.  Inhibitory function of two NFAT family members in lymphoid homeostasis and Th2 development. , 1998, Immunity.

[57]  M. Peter,et al.  Activation of the CD95 (APO-1/Fas) pathway in drug- and γ-irradiation-induced apoptosis of brain tumor cells , 1998, Cell Death and Differentiation.

[58]  C. Y. Wang,et al.  NF-kappaB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. , 1998, Science.

[59]  Z. Ao,et al.  IEX-1L, an Apoptosis Inhibitor Involved in NF-κB-Mediated Cell Survival , 1998 .

[60]  G. Koretzky,et al.  Cutting Edge: A Newly Identified Response Element in the CD95 Ligand Promoter Contributes to Optimal Inducibility in Activated T Lymphocytes , 1998, The Journal of Immunology.

[61]  J. Ashwell,et al.  Cyclosporin A-Sensitive Transcription Factor Egr-3 Regulates Fas Ligand Expression , 1998, Molecular and Cellular Biology.

[62]  P. Krammer,et al.  Surface expression of TRAIL/Apo‐2 ligand in activated mouse T and B cells , 1998, European journal of immunology.

[63]  J. Tschopp,et al.  Biochemical mechanisms of IL-2-regulated Fas-mediated T cell apoptosis. , 1998, Immunity.

[64]  A. Chinnaiyan,et al.  A role for FADD in T cell activation and development. , 1998, Immunity.

[65]  Seamus J. Martin,et al.  Inhibition of TNF-induced apoptosis by NF-κB , 1998 .

[66]  D. Green,et al.  Sensitivity of S49.1 cells to anti-CD95 (Fas/Apo-1)-induced apoptosis: effects of CD95, bcl-2 or bcl-x transduction , 1998, Cell Death and Differentiation.

[67]  D. Green,et al.  DNA damaging agents induce expression of Fas ligand and subsequent apoptosis in T lymphocytes via the activation of NF-kappa B and AP-1. , 1998, Molecular cell.

[68]  Kenneth G. C. Smith,et al.  A dominant interfering mutant of FADD/MORT1 enhances deletion of autoreactive thymocytes and inhibits proliferation of mature T lymphocytes , 1998, The EMBO journal.

[69]  I. Herr,et al.  TRAIL/Apo‐2‐ligand‐induced apoptosis in human T cells , 1998, European journal of immunology.

[70]  Z. Ao,et al.  IEX-1L, an apoptosis inhibitor involved in NF-kappaB-mediated cell survival. , 1998, Science.

[71]  D. Green,et al.  The c-Jun N-terminal kinase cascade plays a role in stress-induced apoptosis in Jurkat cells by up-regulating Fas ligand expression. , 1998, Journal of immunology.

[72]  M J May,et al.  NF-kappa B and Rel proteins: evolutionarily conserved mediators of immune responses. , 1998, Annual review of immunology.

[73]  G. Koretzky,et al.  A newly identified response element in the CD95 ligand promoter contributes to optimal inducibility in activated T lymphocytes. , 1998, Journal of immunology.

[74]  D. Green,et al.  Inhibition of TNF-induced apoptosis by NF-kappa B. , 1998, Trends in cell biology.

[75]  S. Eliason,et al.  Two NFAT Transcription Factor Binding Sites Participate in the Regulation of CD95 (Fas) Ligand Expression in Activated Human T Cells* , 1997, The Journal of Biological Chemistry.

[76]  J. Tschopp,et al.  TRAIL receptors 1 (DR4) and 2 (DR5) signal FADD-dependent apoptosis and activate NF-kappaB. , 1997, Immunity.

[77]  W. Leonard,et al.  Impaired peripheral deletion of activated T cells in mice lacking the common cytokine receptor gamma-chain: defective Fas ligand expression in gamma-chain-deficient mice. , 1997, Journal of immunology.

[78]  G. Evan,et al.  Requirement for the CD95 receptor-ligand pathway in c-Myc-induced apoptosis. , 1997, Science.

[79]  J. Houghton,et al.  Thymineless death in colon carcinoma cells is mediated via fas signaling. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[80]  D. Hanahan,et al.  Fas ligand expression in islets of Langerhans does not confer immune privilege and instead targets them for rapid destruction , 1997, Nature Medicine.

[81]  D. Green,et al.  Unequal Death in T Helper Cell (Th)1 and Th2 Effectors: Th1, but not Th2, Effectors Undergo Rapid Fas/FasL-mediated Apoptosis , 1997, The Journal of experimental medicine.

[82]  S. Eliason,et al.  Regulation of CD95 (Fas) ligand expression by TCR-mediated signaling events. , 1997, Journal of immunology.

[83]  D. Vaux,et al.  Transgenic expression of CD95 ligand on islet beta cells induces a granulocytic infiltration but does not confer immune privilege upon islet allografts. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[84]  J. Pepose,et al.  CD95 ligand (FasL)-induced apoptosis is necessary for corneal allograft survival. , 1997, The Journal of clinical investigation.

[85]  P. Hogan,et al.  Transcription factors of the NFAT family: regulation and function. , 1997, Annual review of immunology.

[86]  T. Mak,et al.  Tumor necrosis factor receptor p55 mediates deletion of peripheral cytotoxic T lymphocytes in vivo , 1996, European journal of immunology.

[87]  J. Tschopp,et al.  Melanoma Cell Expression of Fas(Apo-1/CD95) Ligand: Implications for Tumor Immune Escape , 1996, Science.

[88]  H. Mcdevitt,et al.  The roles of Fas/APO-1 (CD95) and TNF in antigen-induced programmed cell death in T cell receptor transgenic mice. , 1996, Immunity.

[89]  D. Green,et al.  Activation-induced cell death in murine T cell hybridomas. Differential regulation of Fas (CD95) versus Fas ligand expression by cyclosporin A and FK506. , 1996, International immunology.

[90]  I. Herr,et al.  Involvement of the CD95 (APO–1/Fas) receptor/ligand system in drug–induced apoptosis in leukemia cells , 1996, Nature Medicine.

[91]  J. Tschopp,et al.  Peripheral T cells undergoing superantigen-induced apoptosis in vivo express B220 and upregulate Fas and Fas ligand , 1996, The Journal of experimental medicine.

[92]  D. Green,et al.  Fas Ligand-Induced Apoptosis as a Mechanism of Immune Privilege , 1995, Science.

[93]  M. Lenardo,et al.  Induction of apoptosis in mature T cells by tumour necrosis factor , 1995, Nature.

[94]  G. Mills,et al.  Fas (CD95) participates in peripheral T cell deletion and associated apoptosis in vivo. , 1995, International immunology.

[95]  C. Ware,et al.  Fas and activation-induced Fas ligand mediate apoptosis of T cell hybridomas: inhibition of Fas ligand expression by retinoic acid and glucocorticoids , 1995, The Journal of experimental medicine.

[96]  P. Krammer,et al.  Autocrine T-cell suicide mediated by APO-1/(Fas/CD95) , 1995, Nature.

[97]  S. Ju,et al.  Fas(CD95)/FasL interactions required for programmed cell death after T-cell activation , 1995, Nature.

[98]  Seamus J. Martin,et al.  Cell-autonomous Fas (CD95)/Fas-ligand interaction mediates activation-induced apoptosis in T-cell hybridomas , 1995, Nature.

[99]  C. Smith,et al.  Fas ligand mediates activation-induced cell death in human T lymphocytes , 1995, The Journal of experimental medicine.

[100]  R. Flavell,et al.  The liver eliminates T cells undergoing antigen-triggered apoptosis in vivo. , 1994, Immunity.

[101]  R. Budd,et al.  Delayed kinetics of T lymphocyte anergy and deletion in lpr mice. , 1994, Journal of autoimmunity.

[102]  D. Green,et al.  Functional Myc-Max heterodimer is required for activation-induced apoptosis in T cell hybridomas , 1994, The Journal of experimental medicine.

[103]  F. Ramsdell,et al.  Differential ability of Th1 and Th2 T cells to express Fas ligand and to undergo activation-induced cell death. , 1994, International immunology.

[104]  F. Chisari,et al.  Protein transfer of preformed MHC-peptide complexes sensitizes target cells to T cell cytolysis. , 1994, Immunity.

[105]  A. Abbas,et al.  The fas antigen is involved in peripheral but not thymic deletion of T lymphocytes in T cell receptor transgenic mice. , 1994, Immunity.

[106]  D. Loh,et al.  Visualization of peptide-specific T cell immunity and peripheral tolerance induction in vivo. , 1994, Immunity.

[107]  P. Krammer,et al.  Activation induces sensitivity toward APO-1 (CD95)-mediated apoptosis in human B cells. , 1994, Journal of immunology.

[108]  J. Russell,et al.  Autoimmune gld mutation uncouples suicide and cytokine/proliferation pathways in activated, mature T cells , 1993, European journal of immunology.

[109]  G. Evan,et al.  Cooperative interaction between c-myc and bcl-2 proto-oncogenes , 1992, Nature.

[110]  D. Green,et al.  Apoptotic cell death induced by c-myc is inhibited by bcl-2 , 1992, Nature.

[111]  John Calvin Reed,et al.  Inhibition of thymocyte apoptosis and negative antigenic selection in bcl-2 transgenic mice. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[112]  D. Green,et al.  Role for c-myc in activation-induced apoptotic cell death in T cell hybridomas. , 1992, Science.

[113]  Gerard I. Evan,et al.  Induction of apoptosis in fibroblasts by c-myc protein , 1992, Cell.

[114]  Suzanne Cory,et al.  bcl-2 transgene inhibits T cell death and perturbs thymic self-censorship , 1991, Cell.

[115]  S. Korsmeyer,et al.  bcl-2 inhibits multiple forms of apoptosis but not negative selection in thymocytes , 1991, Cell.

[116]  J. Mountz,et al.  Abnormal thymocyte development and production of autoreactive T cells in T cell receptor transgenic autoimmune mice. , 1991, Journal of immunology.

[117]  D. Green,et al.  In vivo administration of monoclonal antibodies to the CD3 T cell receptor complex induces cell death (apoptosis) in immature thymocytes. , 1991, Journal of immunology.

[118]  Y. Kawabe,et al.  Programmed cell death and extrathymic reduction of Vβ8+CD4+ T cells in mice tolerant to Staphylococcus aureus enterotoxin B , 1991, Nature.

[119]  M. Lenardo.  Interleukin-2 programs mouse alpha beta T lymphocytes for apoptosis. , 1991, Nature.

[120]  D. Green,et al.  Activation-induced cell death in T cell hybridomas is due to apoptosis. Morphologic aspects and DNA fragmentation. , 1990, Journal of immunology.

[121]  R. Klausner,et al.  Activation-driven programmed cell death and T cell receptor zeta eta expression. , 1989, Science.

[122]  Beni M. Sahai,et al.  Cyclosporin A inhibits activation-induced cell death in T-cell hybridomas and thymocytes , 1989, Nature.

[123]  Gwyn T. Williams,et al.  Antibodies to CD3/T-cell receptor complex induce death by apoptosis in immature T cells in thymic cultures , 1989, Nature.

[124]  J Salvage,et al.  A matter of life and death. , 1981, Nursing times.